TABLE 5

Activity, efficacy and toxicity outcomes reported in trials evaluating immiune checkpoint inhibitors in malignant pleural mesothelioma

TrialNDrugsORRMedian PFS months
HR (95% CI)
Median OS
HR (95% CI)
Grade ≥3 AE (%)
First line
 DREAM [105]54Durvalumab+CT48%6.918.4NA
 PrE0505 [106]55Durvalumab+CT56.4%6.720.465.5
 CheckMate 743 [7]605Nivolumab+Ipilimumab versus CT40% versus 43%6.8 versus 7.2
1.00 (0.82–1.21)
18.1 versus 14.1 months
0.74 (0.60–0.91)
31 versus 32
First-second line
 NIBIT-MESO [129]40Durvalumab+Tremelimumab28%5.716.6 months18
Second line
 PROMISE-meso [104]144Pembrolizumab versus CT22% versus 6%2.5 versus 3.4 1.06 (0.73–1.53)10.7 versus 12.4 months 1.12 (0.74–1.69)19.4 versus 25.7
Second-third line
NCT02399371 [126]65Pembrolizumab22%4.111.5 monthsNA
 Quispel-Janssen [130]34Nivolumab24%3.6NR29
 MERIT [127]34Nivolumab29%6.117.3 months47
≥ Second line
 KEYNOTE-028 [131]25Pembrolizumab20%5.418 months20
 JAVELIN Solid Tumor [132]53Avelumab9.4%3.9NR9
 INITIATE [133]34Nivolumab+Ipilimumab29%6.2NR38
 IFCT-1501 MAPS2 [134, 135]62
63
Nivolumab
Nivolumab+Ipilimumab
18.5%
25.9%
4
5.6
11.9 months
15.9 months
15
26

N: number of patients; ORR: objective response rate; PFS: progression-free survival; HR: hazard ratio; 95% CI: 95% confidence interval; OS: overall survival; AE: adverse events; CT: chemotherapy; NR: not reported.